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Abstract
Patients with Malignant Mesothelioma (MM) develop unidentified auto-antibodies to MM tumour antigens. This study was
conducted to identify the targets of MM patient auto-antibodies in order to try to understand more of the anti-tumour
response and to determine if these antibodies might be helpful for diagnosis or prognostication. Using MM patient sera in a
Western immunoblott screening strategy, no common immunoreactive proteins were identified. The sera from one long-
term survivor recognised a protein band of 50–60 kDa present in cell lysates from four of five MM cell lines tested. The
immunoreactive proteins in this band were identified by 2D electrophoretic separation of a MM cell line protein lysate,
followed by analysis of excised immunoreactive proteins on a MALDI TOF mass spectrometer and peptide mass
fingerprinting. The immunoreactive proteins identified were vimentin (accession gi55977767) and the ATP synthase (F1-
ATPase) beta chain (accession gi114549 and gi47606749). ELISA assays were developed for antibodies to these proteins.
Neither vimentin (median and 95% CI 0.346; 0.32–0.468 for MM patients, 0.327; 0.308–0.428 for controls) nor ß-F1-ATPase
(0.257; 0.221–0.453 for MM patients, 0.263; 0.22–0.35 for controls) showed significant differences in autoantibody levels
between a group of MM patients and controls. Using a dichotomized antibody level (high, low) for these targets we
demonstrated that vimentin antibody levels were not associated with survival. In contrast, high ß-F1-ATPase antibody levels
were significantly associated with increased median survival (18 months) compared to low ß F1 ATPase antibody levels (9
months; p=0.049). Immunohistochemical analysis on a MM tissue microarray showed cytoplasmic staining in 28 of 33
samples for vimentin and strong cytoplasmic staining in14 and weak in 16 samples for ß-F1-ATPase. Therefore antibodies to
neither vimentin nor ß-F1-ATPase are useful for differential diagnosis of MM, however high antibody levels to ß-F1-ATPase
may be associated with increased survival and this warrants further investigation.
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Introduction
New clinical biomarkers are needed for malignant mesotheli-
oma (MM), an aggressive, asbestos-induced incurable tumour.
The disease is difficult to diagnose and even with the best
available treatments, patients have a median survival of less than
a year after diagnosis and only 1% of patients survive five years
[1,2].
There has been a resurgence of interest in biomarkers for MM.
Most interest has focussed on protein antigens, with mesothelin
being the most promising. Mesothelinhas a sensitivity of 84% at a
specificity of 95% in advanced MM [3], although sensitivity falls to
50% at the time of diagnosis [4] and to 15% in pre-diagnosis serum
[5]. Other markers including megakaryocyte potentiating factor
(MPF), osteopontin, CA125, CA15-3 and hyaluronic acid have
been evaluated alone and in combination with mesothelin
[4,6,7,8,9,10] and no, or only minimal, improvements of diagnostic
sensitivity over mesothelin have been observed. Therefore new
and/or novel candidate biomarkers for MM diagnosis need to be
identified and evaluated.
Rather than focussing on new antigens, another approach to
discovering biomarkers has been to identify anti-tumour auto-
antibodies. During tumourigenisis considerable molecular changes
result in increased and/or aberrant production, altered post-
translational modification and altered cellular distribution of
proteins. This complex suite of abnormal protein expression,
structure and distribution can potentially result in the generation
of a complex auto-antibody profile in individual patients [11].
Auto-antibodies against autologous tumourassociatedantigens
have been detected in many types of cancer including lung cancer
[12,13].
Previously using the serological identification by recombinant
expression cloning (SEREX) approach [14] we identified tumour
associated antigens recognised by MM patient sera, the majority of
specificities were uniquely associated with individual patients
though some common reactivities were observed including against
topoisomerase IIb, U2AF(65) [15] and also ß-F1-ATPase (un-
published data).
Using an one dimensional Western immunoblotting screening
strategy we have previously demonstrated that some MM patients
PLoS ONE | www.plosone.org 1 October 2011 | Volume 6 | Issue 10 | e26515exhibit high titre antibodies to MM proteins expressed on cultured
MM cell lines [16]. However in the previous study there was no
commonly recognised antigenic pattern for MM patients - indeed
at the level of sensitivity of western blotting, patients primarily
appeared to have ‘‘private’’, rather than ‘‘public’’ specificities [16].
In this study we used a different approach, identifying antigenic
proteins intensely recognised by Western immunoblotting of a
patient with a good prognosis for MM and then determining,
using the more sensitive and specific ELISA methodology, whether
in a larger group of MM patients the presence of these antibodies
might be useful in diagnosis or indicative of prognosis.
Results
Auto-antibody profile in MM patients
The auto-antibody profile of serum samples collected from
approximately 150 MM patients within two months of diagnosis
was analysed by one dimensional Western immunoblotting against
total protein lysates from MM cell lines. Individual MM patients
recognised specific protein regions on the membrane at varying
intensities and in the majority of cases patients exhibited multiple
reactivities(Figure 1A). As previously reported [16] there was no
common antibody reactivity for MM patients. No obvious
correlation was observed between the number or intensity of
reactivities and the overall patient group survival.
One individual (Patient ID #145), a 73 year old woman with
pleural epithelial MM demonstrated strong IgG reactivity to a
protein(s) of between 50 and 60 kDa in her sera taken two months
post-diagnosis. This individual was alive 45 months after MM
diagnosis. The immunoreactive protein(s) was present in the total
cell lysates of four of five of the MM cell lines examined and also in
the lysates of the bone osteosarcoma (U2OS) and the colon
carcinoma (HT29) cell lines. No immunoreactivity was detected
against proteins present in the MM line (NO36) or the lung
adenocarcinoma line (A549) (Figure 1B). The immunoreactivity
was evident when sera were titrated out to 1:1600 (data not
shown). Fractionation of the MM cell line, JU77, demonstrated
that the immunodominant protein(s) was present within the Tris-
soluble fraction (data not shown).
Identification of immunoreactive proteins
To identify the immunodominant protein(s) the Tris-soluble
fraction of JU77 cells wasseparated by two dimensional-electropho-
resis and electrophoreticly transferred to PVDF membranes, before
immunostaining. Two densely stained regions were observed,
defined by the approximate pI range 5 to 7 and molecular weight
range 50 to 60 kDa(Figure 2). The regions corresponding to the
immunodominant spots were identified from a parallel G250
Coomassie stained gel and four samples excised from the gel.
Followingpeptide sequencing by mass spectrometry (MS) two of the
samples gave statistically significant matches, vimentin (VIM)
(Accession no. gi55977767) with nine matches (Figure 3) and
ATP synthase beta chain, mitochondrial precursor (ATP5B)
(Accession no. gi 114549 and gi47606749) with nineteen and
twelve matches (Figure 4).
In this study validation experiments were attempted using
immunoblotting in denaturing conditions however Patient #145’s
sera did not recognise recombinant human or bovine vimentin in
Western immunoblotting, and immunoreactivity to MM cell
extract was not inhibited by competitive binding experiments (data
not shown). Similarly, although ß-F1-ATPase was recognised as an
antigen by two other patients in a SEREX screening strategy
(unpublished observations), the clone/recombinant protein which
contained an open reading frame corresponding to the C-terminal
portion of the protein (nt 595–1736) was not recognised by the
Patient #145’s sera by Western immunoblotting. These results are
likely to be due to the effect of the denaturing conditions on the
auto-antibody epitopes [17].
Tissue localisation of vimentin
To confirm that MM cells express vimentinimmunolocalisation
experiments were conducted on independent MM patient samples.
Vimentin was detected in the cytoplasm of tumour cells, non-
malignant stroma and blood vessel endothelial cells. Of the 34 MM
tissues examined, in duplicate, 24 stained intensely positive for
vimentin, 4 cases were weakly or equivocally stained and 6 were
negative. Similarly of the 24 cases of MM effusions, tumour cells
were positively stained in 19 cases, weakly stained in 1 case and 4
were negative (Figure 5).
Frequency of anti-vimentin antibodies in MM patients
An ELISA system was developed using human recombinant
vimentin as an antigen and antibody levels were determined in a
small group of MM patients and healthy controls (Clinical
characteristics presented in Table 1). The majority of control
subjects with no asbestos exposure had anti-vimentin antibodies
present with an absorbance below 0.69. One control individual
Figure 1. Western Immunoblots of MM patient serum with MM
tumour cell line lysates. (A) Representative serum samples from
individual MM patients. Patients segregated into short, medium and
long term survivors. Patient identification number indicated above each
lane. (B) Western immunoblot of cell lysates from five different MM cell
lines and the A549 lung adenocarcinoma, U2OS osteosarcoma and
HT29 colon carcinoma cell lines incubated with serum from a MM
Patient 145. Serum was diluted 1:100. Molecular weights (MW) depicted
to the left of figures.
doi:10.1371/journal.pone.0026515.g001
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the median (95% CI) serum anti-vimentin levels of the MM
patients (0.346; 0.32–0.468) was not significantly different to that
of controls (0.327; 0.308–0.428). Excluding the elevated control
subject, two of the MM patients had antibody levels above the
threshold defined by the control group (ie mean+2 standard
deviations of the mean) including the index patient in which the
original reactivity to vimentin was demonstrated (Figure 6).
Tissue localisation of ß-F1-ATPase
ß-F1-ATPase stained the cytoplasm of MM cells in tissue
sections, in some cells staining was accentuated in the perinuclear
region. Of the 34 MM tissue samples examined, 14 stained
positive for ß-F1-ATPase, 16 cases were weakly or equivocally
stained and 4 were negative. Of the 21 cases of effusion from MM
patients, tumour cells were weakly positively stained in 14 cases,
and negative in 7 cases (Figure 7). There was strong staining for ß-
F1-ATPase in macrophages present in the tumour infiltrate and in
effusions, but it was unclear if this staining was of the macrophage
mitochondria or of phagocytosed material within the cytoplasm of
the macrophage.
Frequency of anti-ß-F1-ATPase antibodies in MM patients
There was no significant difference in the level of antibodies to
ß-F1-ATPase in the group of MM patients (median=0.257; 95%
CI 0.221–0.453) relative to control subjects (0.263; 0.22–0.35).
However four patients had antibody levels greater than 2 standard
deviations above the mean of the control population, including the
patient in whom the anti-ß-F1-ATPase antibodies were originally
identified in, and one of the SEREX positive patients (Figure 8).
Prognostic significance of anti-vimentin and ß-F1-ATPase
antibodies
Antibodies to vimentin and to ß-F1-ATPase were identified
from the sera of an individual who survived 43 months from
diagnosis. No survival advantage was demonstrated when patients
were dichotomised into having high or low concentrations of anti-
vimentin antibodies in the sera (Figure 9A). The group of patients
with high levels of anti-ß-F1-ATPases in the serum had a median
survival of 18 months, which was significantly longer than the
group with low antibody levels (median survival 9 months;
p=0.049) (Figure 9B).
Discussion
Using an immuno-proteomic approach two candidate autoan-
tibody biomarkers for MM were identified; vimentin and ß-F1-
ATPase. Vimentin has previously been evaluated as an immuno-
histochemical marker in MM and to our knowledge ß-F1-ATPase
is a novel marker in this disease.
Vimentin is an intermediate filament characteristic of mesen-
chymal tissue, and has been extensively examined for a potential
role as an immunohistochemical marker for MM tissue diagnosis.
Reports of vimentin expression in MM range from 16% to 100%
(reviewed in [18]). In our small series 74% of MM cells in tissue
and effusions express the protein. As a significant percentage of
lung adenocarcinomas also express the protein it is generally
concluded to be of little value for differential diagnosis for these
diseases [18]. However, as the majority of MM tumours express
the protein this may be an explanation for the inducement of anti-
vimentin antibodies observed in MM patients in this study.
Antibodies to vimentin have been observed in several different
autoimmune conditions including rheumatoid arthritis and sys-
temic lupus erythematosus [19] and also following solid-organ
transplantation [20]. In this present study levels of antibodies to
this protein were not significantly higher in the group of MM
patients examined relative to apparently healthy persons, although
one individual, a 55 year-old man with a history of moderate
autoimmune disease had an elevated antibody level. The
autoimmune status of the MM patients, which may have
Figure 2. Two Dimensional Polyacrylamide Gel Electrophore-
sis. The Tris-soluble fraction of the JU77 cell lysate was separated by 2D
electrophoresis and proteins stained with Coomassie Blue. Proteins
from a parallel gel were transferred to PDVF and incubated with serum
from MM Patient 145 diluted 1:100. Two densely stained IgG reactive
spots were defined by the approximate pI range 5 to 7 and molecular
weight range 50 to 60 kDa, indicated by the circle. Molecular weights
(MW) depicted to the left of figures; isoelectric point (pI) to the top of
figures.
doi:10.1371/journal.pone.0026515.g002
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and of course the identification of antibodies to vimentin may have
been an epiphenomenon.
The second protein identified was the b-subunit of F1-ATPase.
The archetypical ATP synthase is located in the mitochondrial
membrane and is comprised of several subunits. The catalytic b
subunit is the rate-limiting component for ATP production. In
cancer, a common feature is a shift from oxidative phosphoryla-
tion to glycolytic metabolism, known as the Warburg effect [21],
and this is associated with a down regulation of mitochondrial
ATP synthase [22], which has been observed in a variety of
different tumours including colorectal cancer [23], breast cancer
[24] and lung adenocarcinoma [25]. The mechanism by which
ATP synthase is down regulated has not been fully elucidated;
though a specific inhibitory protein has been identified [26]. Low
expressionof ß-F1-ATPase has been associated with shorter
survival times in colorectal cancer patients [27].
In this study ß-F1-ATPase expression was demonstrated in the
cytoplasm of less than half of the MM tumours examined.
Whether a specific tumour expresses the protein may depend on
the degree of oxygenation of the tumour or of the sampled area of
the tumour. In addition to being located in the mitochondria, ß-
F1-ATPase has been shown to be present on the cell membrane of
endothelial cells and tumours of various cell types [28]. Under the
conditions of the current study no surface expression of ß-F1-
ATPase was observed, however it is possible that cell surface ß-F1-
ATPase was masked by tumour-expressed MHC-I antigens [29].
It is not known if anti- b-F1-ATPase antibodies observed in the
present study were generated because the protein was over
expressed or expressed in a different context.
Recently antibodies to ß-F1-ATPase have been demonstrated in
about a third of patients with Alzheimer’s disease [30]. None of the
healthy donors or patients with Parkinson’s disease or atheroscle-
rosis had antibodies though a small number of individuals with
systemic lupus erythematosus and multiple sclerosis were positive
in this assay. In in vitro assays these auto-antibodies induced cell
death by apoptosis. It would be of interest to determine if patients
with other conditions and malignancies also develop antibodies to
this protein.
ß-F1-ATPase was recognised by the sera of a MM patient with a
relatively good survival outcome (45 months), in our cohort of MM
patients less than 3% survive for longer than this time (data not
Figure 3. Sequence alignment of mass peaks matching to Vimentin. Clustal alignment of the Vimentin sequence with trypsin digestion
peptides identified by MS with a matching sequence of confidence 85% or greater.
doi:10.1371/journal.pone.0026515.g003
Figure 4. Sequence alignment of mass peaks matching to ATP5B. Clustal alignment of the ATP5B sequence with trypsin digestion peptides
identified by MS with a matching sequence of confidence 85% or greater.
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PLoS ONE | www.plosone.org 5 October 2011 | Volume 6 | Issue 10 | e26515Figure 5. Immunohistochemicallocalisation of vimentin. Immunohistochemical staining of representative MM samples using anti-vimentin
antibody diluted 1:500 (A) Positive stained MM tumour sample, arrows indicate representative groups of tumour cells; over 90% of the tumour cells
have been stained (B) Non stained MM tumour sample with positively stained stroma. Arrows indicate representative groups of non-staining tumour
cells; less than 10% of tumour cells have been stained. (C) Positively stained MM cells present in a pleural effusion sample. Arrows indicate
representative positive stained MM cells; over 90% of the tumour cells have been stained. (D) Non stained MM tumour cells in a MM patient pleural
effusion. Arrows indicate representative non-staining tumour cells; less than 10% of tumour cells have been stained. Photomicrographs were taken at
6200 magnification.
doi:10.1371/journal.pone.0026515.g005
Table 1. Clinical characteristics and antibody levels for study subjects.
Clinical Data Malignant Mesothelioma Controls
Short term survivors
1 Long term survivors
2
Number 11 11 20
Mean Age (range) 67 (52–82) 63 (42–82) 52 (43–66)
Sex (M:F) 11:0 10:1 16:4
Asbestos Exposure
Y e s 781
N o --8
Unknown 4 3 11
Histology
Epitheliod 5 8 -
Biphasic 1 - -
Not specified 5 3 -
Median Survival (range) 8 (3–11) 28 (14–58) -
Anti-vimentin
3 (OD) 0.33 (0.1–0.81) 0.42 (0.31–0.46) 0.34 (0.27–0.61)
Anti-b-F1-ATPase
3 (OD) 0.18 (0.14–0.43) 0.27 (0.19–0.59) 0.27 (0.23–0.38)
1– Short term survival group; survival ,12 months.
2– Long term survival group; survival .12 months.
3- median 6 95% confidence intervals.
doi:10.1371/journal.pone.0026515.t001
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were not significantly elevated in the group of MM patients
relative to controls; the group of MM patients with relatively high
levels of antibodies to ß-F1-ATPase had a survival advantage over
those with low antibody levels. Whilst the presence of antibodies to
ß-F1-ATPase may be a secondary marker of prognois, it is
interesting to speculate on a more direct role for this protein and
antibodies directed at it. One possibility is that the presence of ß-
F1-ATPase antibodies was indicative of a higher expression of
non-membranous ß-F1-ATPase and that a higher cytoplasmic
expression of this protein is associated with an improved survival
outcome, as is the case for colorectal cancer [27]. Alternatively,
these antibodies may be directed toward cell surface ß-F1-ATPase.
This would be of interest because a number of in vitro studies have
shown that targeting cell surface expressed F1 ATPase by
antibodies [28,31] or by an ATPase inhibitor reduces cell
proliferation by inducing apoptosis and arresting cell cycle at the
G0/G1 check point [32] which may translate to a survival
advantage in patients. Although not clearly associated with
antibody levels, ß-F1-ATPase bound to apolipoprotein-A-1 on
the tumour cell surface has been demonstrated to be a target for
the cytolytic action of gamma-delta T cells [33].
In summary, this study used a two dimensional immuno-
proteomic approach to identify antigens recognised by sera from a
MM patient with a relatively good survival outcome. Vimentin
and ß-F1-ATPase were identified as autoantigens but only anti-ß-
F1-ATPase correlated with survival. These data add to our
knowledge of the role of ß-F1-ATPase in cancer and warrant its
Figure 6. Vimentin ELISA. Levels of antibodies to vimentin were
determined at least in duplicate and individual patient (open diamonds)
and control (closed triangles) values are plotted on the graph. The
defined cut-off value of two standard deviations above the mean of the
control group (excluding the outlier) is depicted by the hashed
horizontal line. The index MM patient sample (Patient 145) result is
indicated by the closed black diamond symbol. There was no significant
difference (ns) between the groups.
doi:10.1371/journal.pone.0026515.g006
Figure 7. Immunohistochemical tissue localisation of b-F1-ATPpase. Immunohistochemical staining of representative MM samples using
anti-b-F1-ATPpase antibody diluted 1:100 (A) Positive stained MM tumour sample, arrows indicate representative groups of tumour cells; over 90% of
the tumour cells have been stained. (B) Non stained MM tumour sample with positively stained macrophage (indicated by arrow); less than 10% of
tumour cells have been stained. (C) Positively stained MM cells present in a pleural effusion sample. Arrows indicate representative positive stained
MM cells; over 90% of the tumour cells have been stained. (D) Non stained MM tumour cells in a MM patient pleural effusion; less than 10% of tumour
cells have been stained. Photomicrographs were taken at a 6200 magnification.
doi:10.1371/journal.pone.0026515.g007
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therapeutic target in MM.
Materials and Methods
Patient samples
Samples were collected from patients presenting to the
respiratory clinics of either Sir Charles Gairdner Hospital or the
Hollywood Specialist Centre in Perth, Western Australia, and
from healthy laboratory volunteers. This study was approved by
the human research ethics committees of Sir Charles Gairdner
and Hollywood Hospitals and all subjects provided written
informed consent. The samples form part of the Australian
Mesothelioma Tissue Bank, a member bank of the Australasian
Biospecimen Network which is supported in part by the Australian
National Health and Medical Research Council. The final
diagnosis in all patients was confirmed by pathologists experienced
in the diagnosis of MM.
Blood samples were collected by routine venepuncture and
allowed to clot for at least 2 h at room temperature, or at 4uC
overnight before processing. Samples were centrifuged at
1,200 rpm for 10 minutes, then the supernatant was removed,
aliquoted and stored at 280uC until use.
Cell Lines
The human malignant mesothelioma cell lines, ONE58, LO68,
NO36, STY51 and JU77 were all derived from the pleural fluid or
tumours of MM patients essentially as described by Manning et al.
[34]. These cell lines have been deposited in CellBank Australia
(Westmead, NSW) and found to be free of contamination and
confirmed to be unique through short tandem repeat profiling.
The human lung adenocarcinoma, A549, colon cancer line
HT29 and bone osteosarcoma U2OSwere purchased from the
American Type Culture Collection (Manassas, VA). Cells were
cultured in RPMI-1640 (Life Technologies, Melbourne, Australia)
supplemented with 20 mM HEPES, 5610
25 M 2-mercaptoeth-
anol, 10% foetal calf serum (Life Technologies) and incubated at
37uC in a 5% CO2 humidified atmosphere. All cells were
harvested when they were about 70–85% confluent.
SDS-Polyacrylamide Gel Electrophoresis and Western
Immunoblotting
Total protein lysates from cell lines were prepared as previously
described [16]. Fractionation of cells was performed as follows,
approximately 2610
8 JU77 cells were trypsinised from tissue
culture flasks, washed and resuspended in ice-cold 40 mM Tris
(pH 7.4) supplemented with protease inhibitors (Boehringer
Mannheim, Germany) and sonicated using a Branford Sonifier
(450) probe sonicator. Cellular DNA was sheared by passing the
sample through a 21 gauge needle, followed by further sonication.
Samples were centrifuged at 20,000 g at 4uC for 15 min and the
Tris-soluble fraction stored at 220uC. The resultant pellet was
resuspended in 10 mM HEPES for 15 minutes on ice, Nonidet P-
40 was added to a final concentration of 1.25% and the sample
vortexed for 30 sec, before being subjected to a further centri-
fugation step. The resultant HEPES soluble fraction was stored at
220uC and the pellet resuspended in 40 mM Tris and lysed by the
addition of 26SDS loading buffer.
Protein was separated by molecular weight on 10% Tris-HCl
gels (BioRad Laboratories, CA). Protein was transferred to
nitrocellulose membrane and Western immunoblotting was
performed as described [35]. Briefly membranes were blocked in
10% skim milk powder and incubated with patient sera diluted
1:100 overnight at 4uC. Bound antibody was detected following
Figure 9. Survival of MM patients dichotomized on antibody
reactivity. Kaplan–Meier survival curves of overall survival (months)
from diagnosis for patients with (A) anti-vimentin and (B) anti-b-F1-
ATPase antibody levels dichotomized below (thick line) and above the
median (thin line).
doi:10.1371/journal.pone.0026515.g009
Figure 8. ß-F1-ATPase ELISA. Levels of antibodies to ß-F1-ATPase
were determined at least in duplicate and individual patient (open
diamonds) and control (closed triangles) values are plotted on the
graph. The defined cut-off value of two standard deviations above the
mean of the control group is depicted by the hashed horizontal line.
The index MM patient sample (Patient 145) result is indicated by the
closed black diamond symbol. The MM patients indicated by grey
symbols were previously identified as being immunopositive to ß-F1-
ATPase by SEREX. There was no significant difference (ns) between the
groups.
doi:10.1371/journal.pone.0026515.g008
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peroxidase (Sigma, NJ) and ECL chemiluminescence reagent (GE
Healthcare, NJ).
Two Dimensional Polyacrylamide Gel Electrophoresis
Proteins within the tris soluble fraction of the equivalent of 10
7
JU77 cells were separated by 2D polyacrylamide electrophoresis
essentially as described [36] Briefly, the tris-soluble fraction was
methanol-precipitated and resuspended in a solubilisation solution
consisting of 5 M urea, 2 M thiourea, 2 mM n-tributyl phosphine,
0.5%pH 3–10Pharmalytecarrierampholytes(Pharmacia,Uppsala,
Sweden), 2% 3-((3-cholamidopropyl), dimethylammonio)1-propa-
nesulfonate (CHAPS), 2% caprylylsulfobetaine, 0.001% Orange G
dye and endonuclease. Protein was separated in the first dimension
using Pharmacia Immobiline immobilized pH-gradient (IPG)18-cm
lineargradient strips at various pI ranges.Samples wereseparated in
the second dimension on denaturing 10% polyacrylamide slab gels
(16618 cm). For each sample two gels were run in parallel, proteins
in the first gel were visualised using 1% Commassie Brilliant Blue
G250 (BioRad) and proteins in the second gel were transferred to
polyvinylenedifluoride membrane (BioRad) for subsequent immu-
noblotting as described above. Two dimensional polyacrylamide gel
electrophoresis was performed by Proteomics International (Ned-
lands, Western Australia).
Peptide-Massfingerprinting
Protein spots were excised from stained gels by hand and
processed for peptide mass fingerprinting as described [36].
Briefly, following tryptic digestion peptides were analysed in a
PerSeptiveBiosystems Voyager DE-STR (Framingham, MA,
USA) matrix-assisted laser desorption/ionization time of-flight
(MALDI-TOF) mass spectrometer. The peptide masses were then
used to search the SWISS-PROT and TrEMBL databases using
the program PeptIdent (http://expasy.proteome.org.au/tools/
peptident.html).
ELISA
ELISA were optimised in preliminary experiments and
performed essentially as described [35]. Wells of a 96-well plate
(MAXISORB, Nunc) were coated with either recombinant human
vimentin (Research Diagnostics, NJ) at 5 mg/ml or yeast ß-F1-
ATPase (a kind gift from Andrew Rodgers, University of Western
Australia) at 1 mg/ml in 100 mMNaHCO3, pH 9.6 overnight at
4uC. Wells were washed three times with PBST, blocked for 1 h in
1% bovine serum albumin (Sigma) and serum samples were
assayed in duplicated at three dilutions 1:50, 1:100 and 1:200.
Following overnight incubation and washing, bound antibody was
detected with alkaline phosphatase conjugated anti-human IgG
(Promega). The wells were incubated with pNPP substrate and the
optical densities (OD) of the wells measured. A positive antibody
response was defined as an OD reading of two standard deviations
or greater above the mean. The ELISAs were highly reproducible
and variance between duplicates did not exceed 8%.
Immunohistochemistry
Immunohistochemistry was performed using standard tech-
niques on atissue microarray of 33 MM tumour tissue samples,
26 MM pleural effusions and a range of malignant and normal
tissues including tonsil, kidney, liver, appendix and colon as
described previously [4]. Primary antibodies, anti-vimentin (Ab-1,
clone V-9, Oncogene, San Diego, CA) and anti-ATP synthase
subunit b (anti-F1F0-ATPase subunit b) (clone 3D5, Molecular
Probes, Eugene, OR) were used at a dilution of 1:500 and 1:100
respectively. A positive result was defined as the presence of stain
in more than 33% of tumour cells as determined by morphology
and staining on parallel slides with calretinin and EMA. Staining
intensity was graded semi-quantitatively as negative, weak (1+),
moderate (2+) or strong (3+).
Statistical Analysis
For comparison between two groups a Mann Whitney test was
applied. Patient survival was analysed using the Kaplan Meier
product limit procedure and patients were stratified into groups
based on whether they expressed high or low antibody levels,
defined as being above or below the median value for antibodies
for a particular protein. A p value of less than 0.05 was considered
significant. Statistical analysis was carried out using the SPSS
version 18 statistical package (IBM Somers NY).
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